Unknown

Dataset Information

0

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.


ABSTRACT: INTRODUCTION:Eculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk. In the United States, meningococcal vaccines are recommended for eculizumab recipients but there are no recommendations on use of long-term antibiotic prophylaxis. We describe characteristics of and meningococcal vaccine and antibiotic receipt in U.S. eculizumab recipients to inform meningococcal disease prevention strategies. METHODS:Persons in the IBM® MarketScan® Research Databases with ?1 claim for eculizumab injection during 2007-2017 were included. Indication for eculizumab use, meningococcal vaccine receipt, and antibiotic receipt were assessed using International Classification of Diseases-9/10 diagnosis codes, vaccine administration procedure codes, and antibiotic codes from pharmacy claims, respectively. RESULTS:Overall 696 persons met the inclusion criteria. Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) were the most common indications for eculizumab use (41% and 37%, respectively); 20% had an undetermined indication. From June 2015 through December 2017, 28% (41/148) of continuously-enrolled patients received ?1 serogroup B vaccine dose. For serogroup ACWY conjugate vaccine, 45% (91/201) of patients received ?1 dose within five years of their most recent eculizumab dose, as recommended. Of eculizumab recipients with outpatient prescription data, 7% (41/579) received antibiotics for ?50% of the period of increased risk for meningococcal disease. CONCLUSION:Many eculizumab recipients had an undetermined indication for eculizumab use; few were up-to-date for recommended meningococcal vaccines or were prescribed antibiotics long-term. These findings can inform further investigation of how to best protect this population from meningococcal disease.

SUBMITTER: Bozio CH 

PROVIDER: S-EPMC7660549 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

Bozio Catherine H CH   Isenhour Cheryl C   McNamara Lucy A LA  

PloS one 20201112 11


<h4>Introduction</h4>Eculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk. In the United States, meningococcal vaccines are recommended for eculizumab recipients but there are no recommendations on use of long-term antibiotic prophylaxis. We describe characteristics of and meningococcal vaccine and antibiotic receipt in U.S. eculizumab recipients to inform meningococca  ...[more]

Similar Datasets

| S-EPMC5532738 | biostudies-literature
| S-EPMC7069623 | biostudies-literature
| S-EPMC7320833 | biostudies-literature
| S-EPMC6821563 | biostudies-literature
| S-EPMC7895889 | biostudies-literature
| S-EPMC7608520 | biostudies-literature
| S-EPMC7534397 | biostudies-literature
| S-EPMC7857313 | biostudies-literature
| S-EPMC5931386 | biostudies-literature
| S-EPMC8422649 | biostudies-literature